Relay’s most cancers drug proves tolerable, however market is unimpressed
ORLANDO, Fla. — Researchers introduced early section trial outcomes on RLY-2608, Relay Therapeutics’ next-generation PI3K inhibitor, on the American Affiliation ...
Tag: tolerable
